{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:25:23Z","timestamp":1795116323366,"version":"4.10.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["194790-2017"],"award-info":[{"award-number":["194790-2017"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In South-Eastern Norway, genetic testing for <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> is offered to breast cancer patients by their treating surgeon or oncologist. Genetic counselling from a geneticist or a genetic counsellor is offered only to those who test positive for a pathogenic variant or have a family history of cancer. This practice is termed \u201cmainstreamed genetic testing\u201d. The aim of this study was to learn about patients\u2019 experience of this healthcare service.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Qualitative in-depth interviews were conducted with 22 breast cancer patients who had been diagnosed during the first half of 2016 or 2017 at one regional and one university hospital and who had been offered testing by their treating physician. A six-phase thematic approach was used to analyse the data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The participants had varied experiences of how and when testing was offered. Three main themes emerged from the analysis: 1. informational and communicational needs and challenges during a chaotic time, 2. the value of genetic testing and 3. the importance of standardised routines for mainstreamed genetic testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite the shock of their diagnosis and the varying experiences they had in respect of how and when testing was offered, all of the participants emphasised that genetic testing had been an important part of their diagnosis and treatment. Our results indicate that there is a need for continuous collaboration between geneticists, surgeons, oncologists and laboratory specialists in order to establish simple and robust routines so as to ensure that all eligible breast cancer patients are offered testing at a point when the test result can have an impact on treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13053-022-00212-6","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T20:02:43Z","timestamp":1644091363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["\u201cIt was an important part of my treatment\u201d: a qualitative study of Norwegian breast Cancer patients\u2019 experiences with mainstreamed genetic testing"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1578-1554","authenticated-orcid":false,"given":"Nina","family":"Str\u00f8msvik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Gravdehaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Lur\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Schlichting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresia","family":"Wangensteen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tone","family":"Vamre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Heramb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovise","family":"M\u00e6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli Marie","family":"Grindedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,5]]},"reference":[{"issue":"23","key":"212_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. Jama. 2017;317(23):2402\u201316. https:\/\/doi.org\/10.1001\/jama.2017.7112.","journal-title":"Jama."},{"issue":"6","key":"212_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med"},{"issue":"8","key":"212_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, et al. Talazoparib in patients with advanced breast Cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1802905.","journal-title":"N Engl J Med"},{"issue":"20","key":"212_CR4","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2217\/fon-2018-0067","volume":"15","author":"AC Armstrong","year":"2019","unstructured":"Armstrong AC, Clay V. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial. Futur Oncol. 2019;15(20):2327\u201335. https:\/\/doi.org\/10.2217\/fon-2018-0067.","journal-title":"Futur Oncol"},{"key":"212_CR5","doi-asserted-by":"publisher","first-page":"g226","DOI":"10.1136\/bmj.g226","volume":"348","author":"K Metcalfe","year":"2014","unstructured":"Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. Bmj. 2014;348:g226. https:\/\/doi.org\/10.1136\/bmj.g226.","journal-title":"Bmj."},{"issue":"1","key":"212_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/annonc\/mdt422","volume":"25","author":"L Cortesi","year":"2014","unstructured":"Cortesi L, Razzaboni E, Toss A, De Matteis E, Marchi I, Medici V, et al. A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1\/2-positive Italian women. Ann Oncol. 2014;25(1):57\u201363. https:\/\/doi.org\/10.1093\/annonc\/mdt422.","journal-title":"Ann Oncol"},{"issue":"2","key":"212_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ygyno.2014.05.028","volume":"134","author":"E Lokich","year":"2014","unstructured":"Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol. 2014;134(2):326\u201330. https:\/\/doi.org\/10.1016\/j.ygyno.2014.05.028.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"212_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/bjc.2013.805","volume":"110","author":"MR Wevers","year":"2014","unstructured":"Wevers MR, Aaronson NK, Verhoef S, Bleiker EM, Hahn DE, Kuenen MA, et al. Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial. Br J Cancer. 2014;110(4):1081\u20137. https:\/\/doi.org\/10.1038\/bjc.2013.805.","journal-title":"Br J Cancer"},{"issue":"3","key":"212_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1365-2354.2005.00574.x","volume":"14","author":"A Ardern-Jones","year":"2005","unstructured":"Ardern-Jones A, Kenen R, Eeles R. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care (Engl). 2005;14(3):272\u201381. https:\/\/doi.org\/10.1111\/j.1365-2354.2005.00574.x.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4","key":"212_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1399-0004.2009.01307.x","volume":"77","author":"EA Lobb","year":"2010","unstructured":"Lobb EA, Barlow-Stewart K, Suthers G, Hallowell N. Treatment-focused DNA testing for newly diagnosed breast cancer patients: some implications for clinical practice. Clin Genet. 2010;77(4):350\u20134. https:\/\/doi.org\/10.1111\/j.1399-0004.2009.01307.x.","journal-title":"Clin Genet"},{"issue":"2","key":"212_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/gim.2015.50","volume":"18","author":"MR Wevers","year":"2016","unstructured":"Wevers MR, Ausems MG, Verhoef S, Bleiker EM, Hahn DE, Brouwer T, et al. Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? Results from a randomized clinical trial. Genet Med. 2016;18(2):137\u201344. https:\/\/doi.org\/10.1038\/gim.2015.50.","journal-title":"Genet Med"},{"issue":"6","key":"212_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/ejhg.2015.196","volume":"24","author":"H H\u00f8berg-Vetti","year":"2016","unstructured":"H\u00f8berg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, et al. BRCA1\/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet. 2016;24(6):881\u20138. https:\/\/doi.org\/10.1038\/ejhg.2015.196.","journal-title":"Eur J Hum Genet"},{"issue":"8","key":"212_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/jso.24763","volume":"116","author":"MR Wevers","year":"2017","unstructured":"Wevers MR, Aaronson NK, Bleiker EMA, Hahn DEE, Brouwer T, van Dalen T, et al. Rapid genetic counseling and testing in newly diagnosed breast cancer: Patients' and health professionals\u2019 attitudes, experiences, and evaluation of effects on treatment decision making. J Surg Oncol. 2017;116(8):1029\u201339. https:\/\/doi.org\/10.1002\/jso.24763.","journal-title":"J Surg Oncol"},{"issue":"11","key":"212_CR14","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00520-012-1427-6","volume":"20","author":"E Zilliacus","year":"2012","unstructured":"Zilliacus E, Meiser B, Gleeson M, Watts K, Tucker K, Lobb EA, et al. Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer. Support Care Cancer. 2012;20(11):2949\u201358. https:\/\/doi.org\/10.1007\/s00520-012-1427-6.","journal-title":"Support Care Cancer"},{"issue":"6","key":"212_CR15","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10897-018-0261-5","volume":"27","author":"S Wright","year":"2018","unstructured":"Wright S, Porteous M, Stirling D, Lawton J, Young O, Gourley C, et al. Patients' views of treatment-focused genetic testing (TFGT): some lessons for the mainstreaming of BRCA1 and BRCA2 testing. J Genet Couns. 2018;27(6):1459\u201372. https:\/\/doi.org\/10.1007\/s10897-018-0261-5.","journal-title":"J Genet Couns"},{"issue":"2","key":"212_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10689-020-00160-x","volume":"19","author":"EM Grindedal","year":"2020","unstructured":"Grindedal EM, J\u00f8rgensen K, Olsson P, Gravdehaug B, Lur\u00e5s H, Schlichting E, et al. Mainstreamed genetic testing of breast cancer patients in two hospitals in south eastern Norway. Familial Cancer. 2020;19(2):133\u201342. https:\/\/doi.org\/10.1007\/s10689-020-00160-x.","journal-title":"Familial Cancer"},{"key":"212_CR17","volume-title":"National guidelines for diagnostics, treatment and follow-up of patients with breast cancer","author":"Group NBC","year":"2021","unstructured":"Group NBC: National guidelines for diagnostics, treatment and follow-up of patients with breast cancer. 2021. https:\/\/nbcgblogfileswordpress.com\/2021\/10\/nasjonalt-handlingsprogram-for-pasienter-med-brystkreft-22102021-17-utgave.pdf Accessed 15 November 2021."},{"issue":"1","key":"212_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ygyno.2015.04.029","volume":"138","author":"T Febbraro","year":"2015","unstructured":"Febbraro T, Robison K, Wilbur JS, Laprise J, Bregar A, Lopes V, et al. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol Oncol. 2015;138(1):109\u201314. https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.029.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"212_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/IGC.0b013e318280f2b4","volume":"23","author":"CB Powell","year":"2013","unstructured":"Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A. Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling? Int J Gynecol Cancer. 2013;23(3):431\u20136. https:\/\/doi.org\/10.1097\/IGC.0b013e318280f2b4.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"212_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10689-016-9953-x","volume":"16","author":"MP Nilsson","year":"2017","unstructured":"Nilsson MP, Winter C, Kristoffersson U, Rehn M, Larsson C, Saal LH, et al. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. Familial Cancer. 2017;16(2):187\u201393. https:\/\/doi.org\/10.1007\/s10689-016-9953-x.","journal-title":"Familial Cancer"},{"issue":"2","key":"212_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psych. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psych"},{"issue":"17","key":"212_CR22","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/jco.2014.57.0085","volume":"33","author":"ML Telli","year":"2015","unstructured":"Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, et al. Phase II study of gemcitabine, carboplatin, and Iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutation-associated breast Cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015;33(17):1895\u2013901. https:\/\/doi.org\/10.1200\/jco.2014.57.0085.","journal-title":"J Clin Oncol"},{"issue":"3","key":"212_CR23","first-page":"353","volume":"93","author":"DO Case","year":"2005","unstructured":"Case DO, Andrews JE, Johnson JD, Allard SL. Avoiding versus seeking: the relationship of information seeking to avoidance, blunting, coping, dissonance, and related concepts. J Med Libr Assoc. 2005;93(3):353\u201362.","journal-title":"J Med Libr Assoc"},{"issue":"2","key":"212_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/1097-0142(19950715)76:2<167::aid-cncr2820760203>3.0.co;2-k","volume":"76","author":"SM Miller","year":"1995","unstructured":"Miller SM. Monitoring versus blunting styles of coping with cancer influence the information patients want and need about their disease. Implications for cancer screening and management. Cancer. 1995;76(2):167\u201377. https:\/\/doi.org\/10.1002\/1097-0142(19950715)76:2<167::aid-cncr2820760203>3.0.co;2-k.","journal-title":"Cancer."},{"issue":"2","key":"212_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/(SICI)1099-1611(199903\/04)8:2<155::AID-PON350>3.0.CO;2-A","volume":"8","author":"LM Ong","year":"1999","unstructured":"Ong LM, Visser MR, van Zuuren FJ, Rietbroek RC, Lammes FB, de Haes JC. Cancer patients' coping styles and doctor-patient communication. Psychooncology. 1999;8(2):155\u201366. https:\/\/doi.org\/10.1002\/(SICI)1099-1611(199903\/04)8:2<155::AID-PON350>3.0.CO;2-A.","journal-title":"Psychooncology."},{"issue":"7","key":"212_CR26","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1200\/JCO.2001.19.7.2049","volume":"19","author":"PA Parker","year":"2001","unstructured":"Parker PA, Baile WF, de Moor C, Lenzi R, Kudelka AP, Cohen L. Breaking bad news about cancer: patients' preferences for communication. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(7):2049\u201356. https:\/\/doi.org\/10.1200\/JCO.2001.19.7.2049.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"212_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10689-013-9644-9","volume":"12","author":"AS Sie","year":"2013","unstructured":"Sie AS, Prins JB, Spruijt L, Kets CM, Hoogerbrugge N. Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes. Familial Cancer. 2013;12(4):675\u201382. https:\/\/doi.org\/10.1007\/s10689-013-9644-9.","journal-title":"Familial Cancer"},{"issue":"12","key":"212_CR28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/pon.1177","volume":"16","author":"LM Timmermans","year":"2007","unstructured":"Timmermans LM, van Zuuren FJ, van der Maazen RW, Leer JW, Kraaimaat FW. Monitoring and blunting in palliative and curative radiotherapy consultations. Psychooncology. 2007;16(12):1111\u201320. https:\/\/doi.org\/10.1002\/pon.1177.","journal-title":"Psychooncology."},{"issue":"2","key":"212_CR29","first-page":"119","volume":"2","author":"RB Flannery Jr","year":"2000","unstructured":"Flannery RB Jr, Everly GS Jr. Crisis intervention: a review. Int J Emerg Ment Health. 2000;2(2):119\u201325.","journal-title":"Int J Emerg Ment Health"},{"key":"212_CR30","volume-title":"Well-Being. Its meaning, measurement and moral importance","author":"J Griffin","year":"1986","unstructured":"Griffin J. Well-Being. Its meaning, measurement and moral importance. Oxford: Clarendon press; 1986."},{"key":"212_CR31","volume-title":"Health behavior and health education theory, research, and practice","author":"K Glanz","year":"2002","unstructured":"Glanz K, Rimer BK, Lewis FM. Health behavior and health education theory, research, and practice. 3rd ed. San Francisco: Jossey-Bass; 2002.","edition":"3"},{"issue":"4","key":"212_CR32","first-page":"450","volume":"29","author":"DP Waldrop","year":"2011","unstructured":"Waldrop DP, O'Connor TL, Trabold N. \u201cWaiting for the other shoe to drop\u201d: distress and coping during and after treatment for breast cancer. J Psychosoc Oncol. 2011;29(4):450\u201373.","journal-title":"J Psychosoc Oncol"},{"issue":"7","key":"212_CR33","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s00520-014-2513-8","volume":"23","author":"LB Dunn","year":"2015","unstructured":"Dunn LB, Langford DJ, Paul SM, Berman MB, Shumay DM, Kober K, et al. Trajectories of fear of recurrence in women with breast cancer. Support Care Cancer. 2015;23(7):2033\u201343. https:\/\/doi.org\/10.1007\/s00520-014-2513-8.","journal-title":"Support Care Cancer"},{"issue":"7","key":"212_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.5694\/j.1326-5377.1999.tb123693.x","volume":"171","author":"S Girgis","year":"1999","unstructured":"Girgis S, Ward JE, Thomson CJ. General practitioners\u2019 perceptions of medicolegal risk. Using case scenarios to assess the potential impact of prostate cancer screening guidelines. Med J Aust. 1999;171(7):362\u20136. https:\/\/doi.org\/10.5694\/j.1326-5377.1999.tb123693.x.","journal-title":"Med J Aust"},{"issue":"3","key":"212_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s10897-010-9279-z","volume":"19","author":"JC Austin","year":"2010","unstructured":"Austin JC. Re-conceptualizing risk in genetic counseling: implications for clinical practice. J Genet Couns. 2010;19(3):228\u201334. https:\/\/doi.org\/10.1007\/s10897-010-9279-z.","journal-title":"J Genet Couns"},{"issue":"3","key":"212_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10689-019-00122-y","volume":"18","author":"N Hallowell","year":"2019","unstructured":"Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M. Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care. Familial Cancer. 2019;18(3):293\u2013301. https:\/\/doi.org\/10.1007\/s10689-019-00122-y.","journal-title":"Familial Cancer"},{"issue":"9280","key":"212_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0140-6736(01)05627-6","volume":"358","author":"K Malterud","year":"2001","unstructured":"Malterud K. Qualitative research: standards, challenges, and guidelines. Lancet. 2001;358(9280):483\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(01)05627-6.","journal-title":"Lancet."}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-022-00212-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-022-00212-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-022-00212-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T20:09:39Z","timestamp":1644091779000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-022-00212-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1186\/s13053-022-00212-6","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,5]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been defined as a quality-of-care study and is thus outside the mandate of the Regional Ethics Committee. It has therefore been approved by the data protection officer at Innlandet Hospital, Akershus University Hospital and Oslo University Hospital. All participants gave their written consent to being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent forms included information about publication of the results of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}